Compare POM & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POM | MRVI |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 555.4M | 449.6M |
| IPO Year | 2025 | 2020 |
| Metric | POM | MRVI |
|---|---|---|
| Price | $0.35 | $3.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $4.57 |
| AVG Volume (30 Days) | ★ 6.4M | 1.2M |
| Earning Date | 12-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $51,210,721.00 | ★ $192,435,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.13 | N/A |
| 52 Week Low | $0.26 | $1.67 |
| 52 Week High | $6.43 | $6.21 |
| Indicator | POM | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 43.10 |
| Support Level | N/A | $3.44 |
| Resistance Level | N/A | $3.59 |
| Average True Range (ATR) | 0.00 | 0.19 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 0.00 | 5.15 |
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.